OIS at AAO 2015

Applied Genetic Technologies Corporation (AGTC)

Nov 12, 2015 10:53am ‐ Nov 12, 2015 11:01am


AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases in ophthalmology. AGTC’s lead product candidates focus on X-linked retinoschisis, achromatopsia and X-linked retinitis pigmentosa, which are inherited orphan diseases of the eye.


  • Mark Shearman, MD, PhD, CSO, Applied Genetic Technologies Corporation (AGTC)

You must be logged in and own this session in order to post comments.